Response to ‘Calcium and phosphate: serum levels versus body balance’  by Charles O'Neill, W.
Calcium and phosphate: serum
levels versus body balance
Kidney International (2008) 74, 246; doi:10.1038/ki.2008.176
To the Editor: We agree completely on the critical view
expressed by Dr O’Neill1 regarding the calcium–phosphate
(Ca–P) product. On the other hand, we question his
conclusion on the minor role of Ca and P in the calcification
process.
We acknowledge that although some studies have proved
an association between vascular calcification and Ca and/or P
levels,2 other studies have not.3 However, a more rational
approach to the understanding of the role played by Ca and P
in vascular calcification is to look not at their serum levels,
but at their daily body balance.
Regardless of the mechanisms, a positive Ca and P balance
is very likely to facilitate vascular calcification. This concept,
first proposed by Hsu4 in his seminal contribution 10 years
ago, is still underestimated. The related concept that Ca and
P concentrations do not reflect balance should always be kept
in mind by the practicing nephrologist. In uremia, a positive
P balance is very common and certainly detrimental. Ca
balance can be negative or positive, depending on treatment
with calcium salts, vitamin D, and Ca levels in the dialysate.
Both a negative and a positive Ca balance can be detrimental,
but in the individual patient we often do not know where we
stand.
Spontaneous precipitation of Ca and P is a simplistic and
incorrect view of the process of vascular calcification, but
their positive balance might be a prerequisite for an increased
formation of calcified soft tissues. In response to the claim
that we need evidence to shift patients from calcium based to
non-calcium-containing phosphate binders, we feel that we
also need evidence that calcium is not harmful to continue
the treatment of hyperphosphatemia with high-dose calcium
salts.
While we await further studies to clarify this issue, we
could start avoiding the confusion by eliminating from
guidelines the Ca–P product, an artificial and useless
parameter.
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I thank the authors for their comments about the use
(or misuse) of the calcium–phosphate product (CaP).
Yokoyama et al.1 found no correlation between serum
calcium and the calcium–phosphorus product, confirming
the point made in my review.2 Because a correlation would
be expected purely on a mathematical basis, this demon-
strates that essentially all the variability in the calcium–-
phosphate product is governed by serum phosphate. As
suggested to me by another nephrologist, we might as well
use the product of the serum phosphorus and the patient’s
shoe size! Not only should the CaP be reconsidered as a
guideline, as recommended by Yokoyama et al., but also it
should be abandoned. The Japanese have taken the correct
approach in focusing on individual calcium and phos-
phorus levels.
Although it is clear that vascular calcification is not
simply the result of precipitation of calcium and phos-
phate, both ions are still critical to the process. Gallieni
and Cozzolino3 propose that total body balances of
calcium and phosphorus rather than circulating levels
are the more important determinants of vascular calcifica-
tion. This is certainly supported by recent trials showing
substantially less vascular calcification with sevelamer than
with calcium-based phosphate binders.4–6 Unfortunately,
measurement of balance is impractical and estimation is
problematic. An obvious question is how mineral balance
could affect sites of calcification without altering circulat-
ing levels. Although serum phosphate levels and the CaP
were the same in patients treated with sevelamer or
calcium salts, the serum calcium concentration was lower
in the sevelamer-treated patients in all three studies and
significantly so in two.4,5 This could be sufficient to reduce
calcification, as a steep relationship exists between calcium
concentration and calcification in vitro.7
I agree with all the authors that calcium and phosphate
have a role in vascular calcification. Whether mineral
balance or individual circulating levels are the appropriate
parameters to follow in our patients is not clear at this
time but we all agree that the CaP is not.
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